2024

Ward, L. M. et al. (2024) Population-based cancer incidence and mortality rates and ratios among adults with intellectual disabilities in Scotland: a retrospective cohort study with record linkage. BMJ Open, 14(8), e084421. (doi: 10.1136/bmjopen-2024-084421) (PMID:39142671) (PMCID:PMC11331995)

Prowse, S. R., Treweek, S., Kiezebrink, K. and Hanna, C. (2024) Evidencing the impacts of health research: Insights from trials reported in the 2018 Australian Engagement and Impact Assessment. Health Promotion Journal of Australia, 35(2), pp. 423-432. (doi: 10.1002/hpja.772) (PMID:37493241)

Lemmon, E., Hanna, C. , Diernberger, K., Paterson, H. M., Wild, S. H., Ennis, H. and Hall, P. S. (2024) Variation in colorectal cancer treatment and outcomes in Scotland: Real world evidence from national linked administrative health data. International Journal of Population Data Science, 9(1), 2179. (doi: 10.23889/ijpds.v9i1.2179) (PMID:38476269) (PMCID:PMC10929767)

Ward, L.A. et al. (2024) Population-based cancer incidence and mortality rates and ratios among adults with intellectual disabilities in Scotland. medRxiv, (doi: 10.1101/2024.01.18.23300433)

Welisch, G., Keith, N. , Jones, R. and Hanna, C. (2024) Creative approaches to reimagining patient and public involvement (PPI) in cancer research. Project Report. OSF. (doi: 10.17605/OSF.IO/243XN).

2023

Gatting, L., Hanna, C. and Robb, K. (2023) Prevalence and characteristics of pictures in cancer screening information: Content analysis of UK print decision support materials. Health Communication, 38(8), pp. 1601-1611. (doi: 10.1080/10410236.2021.2022869) (PMID:34989627)

2022

Hanna, C.R. , Lemmon, E., Hall, P.S., Ennis, H., Morris, E., McLoone, P. , Boyd, K.A. and Jones, R.J. (2022) Cancer trial impact: understanding implementation of the Short Course Oncology Treatment trial findings at a national level. Clinical Oncology, 34(9), pp. 554-560. (doi: 10.1016/j.clon.2022.03.012) (PMID:35370039)

Slevin, F., Hanna, C. R. , Appelt, A., Cunningham, C., Marijnen, C. A. M., Sebag-Montefiore, D. and Muirhead, R. (2022) The long and the short of it: the role of short-course radiotherapy in the neoadjuvant management of rectal cancer. Clinical Oncology, 34(5), e210-e217. (doi: 10.1016/j.clon.2021.12.004) (PMID:34955376)

2021

Hanna, C. R. et al. (2021) Three versus six months of adjuvant doublet chemotherapy for patients with colorectal cancer: a multi-country cost-effectiveness and budget impact analysis. Clinical Colorectal Cancer, 20(3), pp. 236-244. (doi: 10.1016/j.clcc.2021.04.001) (PMID:33992542)

Lemmon, E., Hanna, C. , Hall, P. and Morris, E. (2021) Health economic studies of colorectal cancer and the contribution of administrative data: a systematic review. European Journal of Cancer Care, 30(5), e13477. (doi: 10.1111/ecc.13477) (PMID:34152043)

Hanna, C. R. et al. (2021) Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). Radiation Oncology, 16, 163. (doi: 10.1186/s13014-021-01888-1) (PMID:34446053)

Iveson, T., Hanna, C. , Iveson, P., Zhang, S., Levasseur, A. and Meyerhardt, J. (2021) The early impact of the IDEA collaboration results: how the results changed prescribing practice. JNCI Cancer Spectrum, 5(4), pkab043. (doi: 10.1093/jncics/pkab043) (PMID:34350375) (PMCID:PMC8328095)

Welisch, G. et al. (2021) First in Human: who and what makes a cancer phase 1 trial and why are they so important? Project Report. OSF. (doi: 10.17605/OSF.IO/KWHQF).

Hanna, C. R. et al. (2021) Intensity modulated radiotherapy for rectal cancer in the UK in 2020. Clinical Oncology, 33(4), pp. 213-223. (doi: 10.1016/j.clon.2020.12.011) (PMID:33423883)

Slevin, F., Hanna, C. , Appelt, A. and Muirhead, R. (2021) Launch of the national rectal cancer intensity-modulated radiotherapy guidance. Clinical Oncology, 33(4), pp. 209-213. (doi: 10.1016/j.clon.2020.11.013) (PMID:33341331)

Hanna, C. , Lemmon, E., Ennis, H., Jones, R. , Hay, J., Halliday, R., Clark, S., Morris, E. and Hall, P. (2021) Creation of the first national linked colorectal cancer dataset in Scotland: prospects for future research and a reflection on lessons learned. International Journal of Population Data Science, 6(1), 10. (doi: 10.23889/ijpds.v6i1.1654) (PMID:34007905) (PMCID:PMC8111382)

Hanna, C. R. , Robb, K. A. , Blyth, K. G. , Jones, R. J. and Chalmers, A. J. (2021) Clinician attitudes to using low dose radiotherapy to treat COVID-19 lung disease. International Journal of Radiation Oncology, Biology, Physics, 109(4), pp. 886-890. (doi: 10.1016/j.ijrobp.2020.12.003) (PMID:33309910) (PMCID:PMC7726525)

Hanna, C. R. , Boyd, K. A. and Jones, R. J. (2021) Evaluating cancer research impact: lessons and examples from existing reviews on approaches to research impact assessment. Health Research Policy and Systems, 19, 36. (doi: 10.1186/s12961-020-00658-x) (PMID:33706777) (PMCID:PMC7953786)

Hanna, C. R. , Boyd, K. A. , Wincenciak, J. , Graham, J., Iveson, T., Jones, R. J. and Wilson, R. (2021) Do clinical trials change practice? A longitudinal, international assessment of colorectal cancer prescribing practices. Cancer Treatment and Research Communications, 28, 100445. (doi: 10.1016/j.ctarc.2021.100445) (PMID:34425469)

Hanna, C. R. , O'Cathail, S. M. , Graham, J., Adams, R. and Roxburgh, C. S.D. (2021) Immune checkpoint inhibition as a strategy in the neoadjuvant treatment of locally advanced rectal cancer. Journal of Immunotherapy and Precision Oncology, 4(2), (doi: 10.36401/JIPO-20-31)

2020

Hanna, C. et al. (2020) Pharmacokinetics, safety and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial. Neuro-Oncology, 22(12), pp. 1840-1850. (doi: 10.1093/neuonc/noaa104) (PMID:32347934) (PMCID:PMC7746945)

Hanna, C. R. et al. (2020) Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trial. Trials, 21(935), (doi: 10.1186/s13063-020-04891-1) (PMID:33213530) (PMCID:PMC7675389)

Hanna, C. R. , Gatting, L. P., Boyd, K. A. , Robb, K. A. and Jones, R. J. (2020) Evidencing the impact of cancer trials: insights from the 2014 UK Research Excellence Framework. Trials, 21, 486. (doi: 10.1186/s13063-020-04425-9) (PMID:32503612) (PMCID:PMC7275320)

Hanna, C.R. , Lynskey, D.M., Wadsley, J., Appleyard, S.E., Anwar, S., Miles, E., Gower, J., Hall, E., Coles, C.E. and Hanna, G.G. (2020) Radiotherapy trial set-up in the UK: identifying inefficiencies and potential solutions. Clinical Oncology, 32(4), pp. 266-275. (doi: 10.1016/j.clon.2019.10.004) (PMID:31685377)

Hanna, C. , Lawrie, T. A., Rogozińska, E., Kernohan, A., Jefferies, S., Bulbeck, H., Ali, U. M., Robinson, T. and Grant, R. (2020) Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis. Cochrane Database of Systematic Reviews, 2020(3), CD013261. (doi: 10.1002/14651858.CD013261.pub2) (PMID:32202316)

Sadler, K. A., Hanna, C. , Melia, L. and White, J. (2020) Very unusual case of a primary sinonasal germ cell tumour. BMJ Case Reports, 13(2), e232288. (doi: 10.1136/bcr-2019-232288) (PMID:32060110)

2019

Lawrie, T. A., Hanna, C. R. , Rogozińska, E., Kernohan, A., Vale, L., Bulbeck, H., Ali, U. M. and Grant, R. (2019) Treatment of newly diagnosed glioblastoma in the elderly. Cochrane Database of Systematic Reviews, 2019(2), CD013261. (doi: 10.1002/14651858.cd013261) (PMCID:PMC6369545)

2017

Lorimer, C.F., Hanna, C. , Saran, F., Chalmers, A. and Brock, J. (2017) Challenges to treating older glioblastoma patients: the influence of clinical and tumour characteristics on survival outcomes. Clinical Oncology, 29(11), pp. 739-747. (doi: 10.1016/j.clon.2017.05.010) (PMID:28807361)

2016

Conteduca, V. et al. (2016) Association between early PSA increase and clinical outcome in patients treated with enzalutamide for metastatic castration resistant prostate cancer. Molecular Diagnosis and Therapy, 20(3), pp. 255-263. (doi: 10.1007/s40291-016-0196-1) (PMID:27020582)

Conteduca, V. et al. (2016) Persistent neutrophil to lymphocyte ratio >3 during treatment with enzalutamide and clinical outcome in patients with castration-resistant prostate cancer. PLoS ONE, 11(7), e0158952. (doi: 10.1371/journal.pone.0158952) (PMID:27434372) (PMCID:PMC4951050)

2015

Hanna, C. and Jones, R. J. (2015) Emerging treatments for recurrent prostate cancer. Future Oncology, 11(21), pp. 2873-2880. (doi: 10.2217/fon.15.228) (PMID:26436556)

2013

Johnston, M., Guo, L., Back, M., Guminski, A., Lee, A., Hanna, C. , Veivers, D., Wignall, A. and Eade, T. (2013) Intensity-modulated radiotherapy using simultaneous-integrated boost for definitive treatment of locally advanced mucosal head and neck cancer: Outcomes from a single-institution series. Journal of Medical Imaging and Radiation Oncology, 57(3), pp. 356-363. (doi: 10.1111/1754-9485.12033) (PMID:23721147)

Hanna, C. , Dhaun, N., Squires, M. and Watson, S. (2013) Haemolytic anaemia complicating the concurrent use of allopurinol & azathioprine after kidney transplantation. International Journal of Basic and Clinical Pharmacology, 2(3), pp. 330-332. (doi: 10.5455/2319-2003.ijbcp20130619)

Articles

Ward, L. M. et al. (2024) Population-based cancer incidence and mortality rates and ratios among adults with intellectual disabilities in Scotland: a retrospective cohort study with record linkage. BMJ Open, 14(8), e084421. (doi: 10.1136/bmjopen-2024-084421) (PMID:39142671) (PMCID:PMC11331995)

Prowse, S. R., Treweek, S., Kiezebrink, K. and Hanna, C. (2024) Evidencing the impacts of health research: Insights from trials reported in the 2018 Australian Engagement and Impact Assessment. Health Promotion Journal of Australia, 35(2), pp. 423-432. (doi: 10.1002/hpja.772) (PMID:37493241)

Lemmon, E., Hanna, C. , Diernberger, K., Paterson, H. M., Wild, S. H., Ennis, H. and Hall, P. S. (2024) Variation in colorectal cancer treatment and outcomes in Scotland: Real world evidence from national linked administrative health data. International Journal of Population Data Science, 9(1), 2179. (doi: 10.23889/ijpds.v9i1.2179) (PMID:38476269) (PMCID:PMC10929767)

Ward, L.A. et al. (2024) Population-based cancer incidence and mortality rates and ratios among adults with intellectual disabilities in Scotland. medRxiv, (doi: 10.1101/2024.01.18.23300433)

Gatting, L., Hanna, C. and Robb, K. (2023) Prevalence and characteristics of pictures in cancer screening information: Content analysis of UK print decision support materials. Health Communication, 38(8), pp. 1601-1611. (doi: 10.1080/10410236.2021.2022869) (PMID:34989627)

Hanna, C.R. , Lemmon, E., Hall, P.S., Ennis, H., Morris, E., McLoone, P. , Boyd, K.A. and Jones, R.J. (2022) Cancer trial impact: understanding implementation of the Short Course Oncology Treatment trial findings at a national level. Clinical Oncology, 34(9), pp. 554-560. (doi: 10.1016/j.clon.2022.03.012) (PMID:35370039)

Slevin, F., Hanna, C. R. , Appelt, A., Cunningham, C., Marijnen, C. A. M., Sebag-Montefiore, D. and Muirhead, R. (2022) The long and the short of it: the role of short-course radiotherapy in the neoadjuvant management of rectal cancer. Clinical Oncology, 34(5), e210-e217. (doi: 10.1016/j.clon.2021.12.004) (PMID:34955376)

Hanna, C. R. et al. (2021) Three versus six months of adjuvant doublet chemotherapy for patients with colorectal cancer: a multi-country cost-effectiveness and budget impact analysis. Clinical Colorectal Cancer, 20(3), pp. 236-244. (doi: 10.1016/j.clcc.2021.04.001) (PMID:33992542)

Lemmon, E., Hanna, C. , Hall, P. and Morris, E. (2021) Health economic studies of colorectal cancer and the contribution of administrative data: a systematic review. European Journal of Cancer Care, 30(5), e13477. (doi: 10.1111/ecc.13477) (PMID:34152043)

Hanna, C. R. et al. (2021) Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). Radiation Oncology, 16, 163. (doi: 10.1186/s13014-021-01888-1) (PMID:34446053)

Iveson, T., Hanna, C. , Iveson, P., Zhang, S., Levasseur, A. and Meyerhardt, J. (2021) The early impact of the IDEA collaboration results: how the results changed prescribing practice. JNCI Cancer Spectrum, 5(4), pkab043. (doi: 10.1093/jncics/pkab043) (PMID:34350375) (PMCID:PMC8328095)

Hanna, C. R. et al. (2021) Intensity modulated radiotherapy for rectal cancer in the UK in 2020. Clinical Oncology, 33(4), pp. 213-223. (doi: 10.1016/j.clon.2020.12.011) (PMID:33423883)

Slevin, F., Hanna, C. , Appelt, A. and Muirhead, R. (2021) Launch of the national rectal cancer intensity-modulated radiotherapy guidance. Clinical Oncology, 33(4), pp. 209-213. (doi: 10.1016/j.clon.2020.11.013) (PMID:33341331)

Hanna, C. , Lemmon, E., Ennis, H., Jones, R. , Hay, J., Halliday, R., Clark, S., Morris, E. and Hall, P. (2021) Creation of the first national linked colorectal cancer dataset in Scotland: prospects for future research and a reflection on lessons learned. International Journal of Population Data Science, 6(1), 10. (doi: 10.23889/ijpds.v6i1.1654) (PMID:34007905) (PMCID:PMC8111382)

Hanna, C. R. , Robb, K. A. , Blyth, K. G. , Jones, R. J. and Chalmers, A. J. (2021) Clinician attitudes to using low dose radiotherapy to treat COVID-19 lung disease. International Journal of Radiation Oncology, Biology, Physics, 109(4), pp. 886-890. (doi: 10.1016/j.ijrobp.2020.12.003) (PMID:33309910) (PMCID:PMC7726525)

Hanna, C. R. , Boyd, K. A. and Jones, R. J. (2021) Evaluating cancer research impact: lessons and examples from existing reviews on approaches to research impact assessment. Health Research Policy and Systems, 19, 36. (doi: 10.1186/s12961-020-00658-x) (PMID:33706777) (PMCID:PMC7953786)

Hanna, C. R. , Boyd, K. A. , Wincenciak, J. , Graham, J., Iveson, T., Jones, R. J. and Wilson, R. (2021) Do clinical trials change practice? A longitudinal, international assessment of colorectal cancer prescribing practices. Cancer Treatment and Research Communications, 28, 100445. (doi: 10.1016/j.ctarc.2021.100445) (PMID:34425469)

Hanna, C. R. , O'Cathail, S. M. , Graham, J., Adams, R. and Roxburgh, C. S.D. (2021) Immune checkpoint inhibition as a strategy in the neoadjuvant treatment of locally advanced rectal cancer. Journal of Immunotherapy and Precision Oncology, 4(2), (doi: 10.36401/JIPO-20-31)

Hanna, C. et al. (2020) Pharmacokinetics, safety and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial. Neuro-Oncology, 22(12), pp. 1840-1850. (doi: 10.1093/neuonc/noaa104) (PMID:32347934) (PMCID:PMC7746945)

Hanna, C. R. et al. (2020) Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trial. Trials, 21(935), (doi: 10.1186/s13063-020-04891-1) (PMID:33213530) (PMCID:PMC7675389)

Hanna, C. R. , Gatting, L. P., Boyd, K. A. , Robb, K. A. and Jones, R. J. (2020) Evidencing the impact of cancer trials: insights from the 2014 UK Research Excellence Framework. Trials, 21, 486. (doi: 10.1186/s13063-020-04425-9) (PMID:32503612) (PMCID:PMC7275320)

Hanna, C.R. , Lynskey, D.M., Wadsley, J., Appleyard, S.E., Anwar, S., Miles, E., Gower, J., Hall, E., Coles, C.E. and Hanna, G.G. (2020) Radiotherapy trial set-up in the UK: identifying inefficiencies and potential solutions. Clinical Oncology, 32(4), pp. 266-275. (doi: 10.1016/j.clon.2019.10.004) (PMID:31685377)

Hanna, C. , Lawrie, T. A., Rogozińska, E., Kernohan, A., Jefferies, S., Bulbeck, H., Ali, U. M., Robinson, T. and Grant, R. (2020) Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis. Cochrane Database of Systematic Reviews, 2020(3), CD013261. (doi: 10.1002/14651858.CD013261.pub2) (PMID:32202316)

Sadler, K. A., Hanna, C. , Melia, L. and White, J. (2020) Very unusual case of a primary sinonasal germ cell tumour. BMJ Case Reports, 13(2), e232288. (doi: 10.1136/bcr-2019-232288) (PMID:32060110)

Lawrie, T. A., Hanna, C. R. , Rogozińska, E., Kernohan, A., Vale, L., Bulbeck, H., Ali, U. M. and Grant, R. (2019) Treatment of newly diagnosed glioblastoma in the elderly. Cochrane Database of Systematic Reviews, 2019(2), CD013261. (doi: 10.1002/14651858.cd013261) (PMCID:PMC6369545)

Lorimer, C.F., Hanna, C. , Saran, F., Chalmers, A. and Brock, J. (2017) Challenges to treating older glioblastoma patients: the influence of clinical and tumour characteristics on survival outcomes. Clinical Oncology, 29(11), pp. 739-747. (doi: 10.1016/j.clon.2017.05.010) (PMID:28807361)

Conteduca, V. et al. (2016) Association between early PSA increase and clinical outcome in patients treated with enzalutamide for metastatic castration resistant prostate cancer. Molecular Diagnosis and Therapy, 20(3), pp. 255-263. (doi: 10.1007/s40291-016-0196-1) (PMID:27020582)

Conteduca, V. et al. (2016) Persistent neutrophil to lymphocyte ratio >3 during treatment with enzalutamide and clinical outcome in patients with castration-resistant prostate cancer. PLoS ONE, 11(7), e0158952. (doi: 10.1371/journal.pone.0158952) (PMID:27434372) (PMCID:PMC4951050)

Hanna, C. and Jones, R. J. (2015) Emerging treatments for recurrent prostate cancer. Future Oncology, 11(21), pp. 2873-2880. (doi: 10.2217/fon.15.228) (PMID:26436556)

Johnston, M., Guo, L., Back, M., Guminski, A., Lee, A., Hanna, C. , Veivers, D., Wignall, A. and Eade, T. (2013) Intensity-modulated radiotherapy using simultaneous-integrated boost for definitive treatment of locally advanced mucosal head and neck cancer: Outcomes from a single-institution series. Journal of Medical Imaging and Radiation Oncology, 57(3), pp. 356-363. (doi: 10.1111/1754-9485.12033) (PMID:23721147)

Hanna, C. , Dhaun, N., Squires, M. and Watson, S. (2013) Haemolytic anaemia complicating the concurrent use of allopurinol & azathioprine after kidney transplantation. International Journal of Basic and Clinical Pharmacology, 2(3), pp. 330-332. (doi: 10.5455/2319-2003.ijbcp20130619)

Research Reports or Papers

Welisch, G., Keith, N. , Jones, R. and Hanna, C. (2024) Creative approaches to reimagining patient and public involvement (PPI) in cancer research. Project Report. OSF. (doi: 10.17605/OSF.IO/243XN).

Welisch, G. et al. (2021) First in Human: who and what makes a cancer phase 1 trial and why are they so important? Project Report. OSF. (doi: 10.17605/OSF.IO/KWHQF).